P. Trask

165MO Patient (pt) preference for the pertuzumab-trastuzumab fixed-dose combination for subcutaneous use (PH FDC SC) in HER2-positive early breast cancer (EBC): Primary analysis of the open-label, randomised crossover PHranceSCa study

M. Burotto, L. Fallowfield, J. O’Shaughnessy, 2020 .

Assessment of psychological distress in prospective bone marrow transplant patients

P. Steele, P. Parker, J. Ferrara, 2002, Bone Marrow Transplantation.

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.

A. Schneeweiss, D. Miles, M. Campone, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.